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giogenic, neurotrophic, and neuroprotective molecule that is
the endogenous inhibitor of vascular endothelial growth factor
(VEGF) in the retina. An ex vivo gene therapy approach based
on transgenic overexpression of PEDF in the eye is assumed to
rebalance the angiogenic-antiangiogenic milieu of the retina,
resulting in growth regression of choroidal blood vessels, the
hallmark of neovascular age-related macular degeneration.
Here, we show that rat pigment epithelial cells can be efficiently
transfected with the PEDF-expressing non-viral hyperactive
Sleeping Beauty transposon system delivered in a form free of
antibiotic resistance marker miniplasmids. The engineered
retinal and iris pigment epithelium cells secrete high (141 ±
13 and 222 ± 14 ng) PEDF levels in 72 hr in vitro. In vivo
studies showed cell survival and insert expression during at
least 4 months. Transplantation of the engineered cells to the
subretinal space of a rat model of choroidal neovascularization
reduces almost 50% of the development of new vessels.Received 3 October 2016; accepted 7 August 2017;
http://dx.doi.org/10.1016/j.omtn.2017.08.001.
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Elevated levels of vascular endothelial growth factor (VEGF) have
been linked to the development of several ocular pathologies,
including neovascular age-related macular degeneration (nAMD)
and diabetic retinopathy.1 VEGF is a potent endothelial mitogen
and vascular permeability factor and is considered the principal
driver of choroidal neovascularization (CNV).2 The appropriate bal-
ance between the pro-angiogenic VEGF and the anti-angiogenic pig-
mented epithelium-derived factor (PEDF) in the retina could be
essential to prevent the development of CNV.3 PEDF was first iden-Molecular The
This is an open access article under the CC BY-Ntified in retinal pigment epithelial (RPE) cells, but it is expressed
in many cell types in the eye. In addition to a potent antiangiogenic
effect, PEDF has neurotrophic and neuroprotective properties.4
The current treatment for neovascular retinal diseases is the inhibi-
tion of VEGF, specifically by the intravitreal injection of ranibizu-
mab, the Fab fragment of a humanized antibody against VEGF
(Lucentis, Novartis Pharma, Basel, Switzerland), aflibercept, a re-
combinant fusion protein (Eylea, Bayer Plc, UK), or bevacizumab,
the whole humanized antibody against VEGF (Avastin, Roche, Basel,
Switzerland). The injection of these anti-VEGFs controls CNV in
nAMD patients, and in 30%–40% of cases, improves vision signifi-
cantly.2,5–8 However, effective treatment requires frequent, costly,9,10
and life-long intraocular injections, and can be associated with side
effects, such as endophthalmitis, ocular hypertension, and retinal
detachment.11,12
To avoid life-long, frequent intraocular injections, long-term delivery
systems, e.g., nanoparticles,13 have been studied to transfer
plasmids with the therapeutic gene. Likewise, many different antian-
giogenic molecules are under study, such as sFLT01,14 Flt23K,15 or
angiopoietin-1.16rapy: Nucleic Acids Vol. 9 December 2017 ª 2017 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. PEDF Quantification
Total PEDF secreted by cells seeded was quantified by ELISA every 24 hr. (A) PEDF
produced by ARPE-19 cells. (B) PEDF secreted by RPE and IPE cells. There was no
detectable PEDF in control Venus-transfected samples. Data are presented as
mean ± SEM (n = 5). *p < 0.05.
Molecular Therapy: Nucleic AcidsThe delivery of anti-angiogenic factors to the retina using gene
therapy could be approached by the direct administration17 or trans-
plantation of ex vivo engineered RPE cells expressing anti-angiogenic
factors.18 In a number of cases, the gene is delivered using adeno-
associated virus (AAV) vectors; however, the required re-administra-
tion may compromise efficacy19 and might induce an immune
response. Recent clinical studies showed that intravitreal sFLT0120
and subretinal endostatin/angiostatin21 injections seemed to be safe
and well tolerated, although the efficacy in the CNV reduction was
not confirmed. The Sleeping Beauty (SB) system that we proposed
has a reduced immunogenicity,22 improved safety/toxicity pro-
files,23,24 and a relaxed limitation on the size of expression cas-
settes.25,26 We combined the non-viral hyperactive SB (SB100X)
transposon system and the pFAR4 vector (free of antibiotic resistance
genes) to deliver the PEDF gene to pigment epithelial cells. We trans-
plant the ex vivo engineered, PEDF-expressing cells subretinally. Both
the SB100X transposase and the PEDF gene are carried by pFAR4
derivatives. We hypothesized that we could provide efficient gene de-
livery, sustained gene expression, as well as improved biosafety by
avoiding the potential transfer of antibiotic resistance genes into the
host cell. The transposon-mediated integration of the PEDF gene2 Molecular Therapy: Nucleic Acids Vol. 9 December 2017into pigment epithelial cells would result in the continuous expression
of the PEDF that would then inhibit the further development or even
regression of CNV.24,27,28
Here, we report on the efficient transfection of rat RPE and iris
pigment epithelial cells (IPEs) with the PEDF gene using the
SB100X transposon system delivered by pFAR4 plasmids, the sus-
tained release of recombinant PEDF in vitro, the proper localization
of transfected cell transplanted subretinally, and the inhibition of neo-
vascularization in a rat model of CNV.
RESULTS
PEDFProduction byARPE-19 andRat Primary IPE andRPECells
Transfected with the PEDF Gene
Before transfection with the SB transposon vector expressing PEDF,
cells were characterized to confirm that they retained their expected
phenotype in culture (Figure S1). ARPE-19 cells (Figures S1A–S1I)
were positive for RPE65 and CRALBP, primary RPE cells (Figures
S1J–S1O) were positive for RPE65 and Bestrophin, and IPE cells
reacted positively for cytokeratin 18 (CK18) (Figures S1P–S1R).
Quantification by ELISA detected continuous secretion of PEDF in
the engineered ARPE-19, primary RPE, and IPE cells over a 72-hr
period (Figures 1A and 1B). Importantly, PEDF secretion was
increased from 24 to 72 hr in all three cell types (Figures 1A and
1B), reaching significance for IPE cells (p = 0.011). ARPE-19 cells
secreted approximately 50-fold more PEDF than IPE or RPE primary
cells did (10,434 ± 1,820 ng/mL secreted by ARPE-19 and 141 ±
13 ng/mL and 222 ± 14 ng/mL secreted by RPE and IPE cells, respec-
tively). There was no detectable PEDF in control Venus-transfected
samples.
PEDF secretion in vitro was maintained over 8 weeks for the three
cell types studied (Figure 2) when transfected with PEDF and
SB100X. A very significant change in PEDF levels was detected in
IPE cells (p < 0.01). These results are in accordance with the ones ob-
tained in previous studies.28
In addition to PEDF, a His-tagged version of PEDF (PEDF-His) was
also transfected into ARPE-19, RPE, and IPE cells. Both forms of
PEDF were easily detectable, as illustrated by western blots of culture
supernatants of ARPE-19, RPE, and IPE cells (Figure 3).
Localization of Transplanted Venus-Transfected Cells in the
Subretinal Space
Engineered Venus reporter-expressing cells were transplanted into
the subretinal space of the rat. Cell localization of transplanted cells
was assessed in flat mount retinas and cross-section cryosections of
eyes 7 days after transplantation (Figures 4 and S2). Importantly,
Venus-positive cells were located mostly around the site of injection
(Figures 4A–4D). Flat mount images showed cells transfected with
Venus and labeled with CellBrite to confirm that the Venus-positive
cells were the ones injected (Figures 4E–4L). In addition, flat mounts
of the RPE/choroid complex observed by confocal microscopy
showed that the Venus-transplanted cells were located close to the
Figure 2. PEDF Detection in the Supernatants during 8 Weeks
PEDF secretion accumulated during 72 hr was measured by ELISA at different time
points (days 3, 6, 9, 12, 15, 21, 28, and 56). (A and B) Diagrams show PEDF
accumulation in ARPE-19 cells (A) and RPE and IPE cells (B). Data are presented as
mean ± SEM (n = 3). **p < 0.01.
Figure 3. PEDF and PEDF-His Secretion by Western Blot
Analysis of ARPE-19, RPE, and IPE cells’ supernatants. Both plasmids were
able to transfect cells and produce the protein of interest with a similar efficiency.
(A) Densitometric analysis of PEDF detection. (B) Image of PEDF detection by
western blot (WB).
www.moleculartherapy.orgtight junctions (labeled with ZO-1) of the native RPE, as illustrated in
the orthogonal stack image (Figure S3).
Venus-transfected cells were stained with CellBrite and transplanted
into the subretinal space. Inmunostaining for RPE65 was done, but
transplanted RPE cell staining was not clear, as described by Pet-
rus-Reurer et al.29 (Figure 5). CellBrite marked organelles and the cy-
toplamic membrane of cells, and it confirmed that Venus-positive
cells were the transplanted cells, even if they were not positive for
RPE65.
The correct location of transfected cells was also verified in eye sam-
ples transplanted with 1,000 IPE or RPE cells (Figure 6) transfected
with Venus and previously stained with CellBrite. These samples
showed the location of RPE (Figures 6A–6I) and IPE (Figures 6J–
6W) cell clusters 1 week after transplantation.
PEDF-His production was tested 2 weeks after the transplantation.
Confocal analysis of retinal flat mounts stained with antibodies to
PEDF and 6-His peptide showed that the transplanted IPE cells
were alive and produced PEDF-His in the subretinal space (Fig-ure S4A). The orthogonal projections confirmed localization of the
injected cells in the subretinal space (Figure S4B).
Transfected Cells Survive Long-Term in the Subretinal Space
Cell survival was evaluated in flat mounts of retinas from rats trans-
planted with Venus-transfected rat IPE and RPE primary cells. In
the flatmounts, bothRPE- and IPE-Venus-positive cells were detected
at 7 days, 14 days, and 4 months after transplantation (Figure 7). In
addition, a Z-orthogonal image showed the correct location in the sub-
retinal space of the RPE-transplanted cells for 4 months (Figure S5).
In Vivo Efficacy Study
The effect of PEDF secretion was monitored 12 days after laser-CNV
induction and 10 days post-subretinal transplantation of PEDF-ex-
pressing primary cells. The CNV area was stained with caveolin-1
antibody. It is evident from the photomicrographs (Figure 8A) and
the area of CNV quantification (Figure 8B) that the area of CNV is
41% in the three rats transplanted with 10,000 PEDF-expressing
IPE cells and 46% in the three rats transplanted with 20,000 PEDF-ex-
pressing RPE cells compared to the area of CNV in rats injected with
saline. By contrast, no difference in the CNV lesion size was detected
in the four control groups (Figure 8C).
DISCUSSION
We have previously reported the stable and efficient transgene integra-
tion in bovine, human, and immortalized rat RPE cells transfected with
PEDF gene using the SB100X transposon system.28,30 Here, we show
that ARPE-19 or rat primary RPE and IPE cells can be transfected by
the PEDF expression construct using the SB100X transposase, bothMolecular Therapy: Nucleic Acids Vol. 9 December 2017 3
Figure 4. Distribution of the Primary Cells Injected
Representative images of the primary cells in the subretinal space. (A) Cross retinal section showing Venus-positive cells near to the photoreceptor layer at the site of
injection. (B–D) Cross sectional retinal areas injected with primary cells transfected with Venus (scale bar, 100 mm). (E–H) Flat mount retinas injected with rat RPE cells
transfected with Venus (green) and labeled with CellBrite (red) and DAPI (blue) from ONL (E) to RPE (F–H). (I–L) The highlighted with rectangles were examined at
higher magnification with confocal super-resolution imaging. CellBrite labeled the plasmatic membrane and DAPI labeled the nuclei. Scale bar, 50 mm. CB, CellBrite;
RPE, retinal pigment epithelium; ONL, outer nuclear layer.
Molecular Therapy: Nucleic Acidsencoded in pFARminiplasmids. Cells secrete PEDF for at least 8 weeks
into the culturemedia in vitro and 2weeks transplanted subretinally.To
our knowledge, this is the first demonstration that PEDF is expressed
subretinally by PEDF-transfected primary cells for at least 2 weeks,
and, as shown previously in similar studies,30 the transplanted cells
reduce neovascularization in a rat model of CNV. Likewise, Venus-
transfected rat IPE and RPE cells produced Venus fluorescent protein
in the subretinal space for at least 4 months after transplantation.
Because the use on anti-VEGFs for the treatment of neovascular
AMD is effective in only 30%–40% of patients and because it is neces-
sary that anti-VEGFs be injected intraocularly every 4–8 weeks for the
life of the patient and because the treatment is costly9,10 and may elicit4 Molecular Therapy: Nucleic Acids Vol. 9 December 2017significant side effects,11,12,31,32 it is imperative that novel, long-last-
ing, andmore effective treatments be discovered.18We have proposed
the transplantation of PEDF-transfected pigment epithelial cells as a
long-term alternative to the frequent intraocular injections of anti-
VEGFs for the treatment for nAMD.
Given that gene delivery by viral vectors has significant limitations,33
we have investigated the use of the non-viral SB100X coupled with
pFAR miniplasmid technology. The SB100X transposon vector pro-
vides efficient integration of the therapeutic gene into the host cell’s
genome and sustained gene expression in many cell types,34,35
including RPE and IPE cells,28 as we report here. In addition, Sleeping
Beauty is relatively safe because unlike integrating viral vectors, it
Figure 5. Injected Cell Location
(A–H) Representative fluorescence image of the retinal cross section showing rat RPE cells transfected with Venus (green) (A and E), labeled with CellBrite (white) (C andG), and
immunostainedwithRPE65 (red) (B,D, F, andH).Nucleiwere labeledwithDAPI (blue). Scale bar, 20mm.CB,CellBrite; RPE, retinal pigment epithelium;ONL, outer nuclear layer.
www.moleculartherapy.orgdoes not target transcriptionally active genomic sequences.36–38
Furthermore, the use of pFAR4 plasmids would not transfer antibiotic
resistance genes into the patient, and is thus safer than other plasmids.
It eliminates the risk of colonization of endogenous flora, allergic
reactions in susceptible patients to antibiotics, and the risk for
horizontal gene transfer that could provide pathogenic bacteria
with resistance to antibiotics that are used to treat humans.39 In
our approach, ARPE-19 and primary IPE and RPE cells were
transfected ex vivo, followed by transplantation into the subretinal
space. The ex vivo strategy ensures that only the target cells are
treated, which is a task that can be difficult using an in vivo delivery
approach.
Here, we also report that the PEDF-expression RPE as well IPE cells
transplanted into the subretinal space do not migrate to other layers
of the retina and stay localized in the RPE layer. This is a critical issuefor the treatment of nAMD because the secretion of PEDFmust occur
at the interface of the neural retina and Bruch’s membrane to prevent
the choroidal vessels from penetrating through the Bruch’s mem-
brane into the subretinal space.
In order to extend the therapeutic effect, plasmids encoding anti-
angiogenic genes were delivered by nanoparticles and injected intra-
venously.13 However, the frequent injections of nanoparticles might
lead to systemic toxicity, making this approach unlikely to become
clinically relevant. The delivery of anti-angiogenic genes by viral vec-
tors and even the transplantation of cells transfected ex vivo using
viral vectors (AAV) followed by transplantation have been demon-
strated. This approach has significant side effects, such as induced
innate immune response.40–42 In addition, the high cost of vector pro-
duction43,44 coupled with other safety concerns will preclude the use
of viral vectors to become clinically widespread. In contrast to viralMolecular Therapy: Nucleic Acids Vol. 9 December 2017 5
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Figure 7. Long-Term Venus Expression by
Transplanted Cells
Confocal images of Venus-positive cells in flat mount of
retinas showing IPE and RPE cells 7 days, 15 days, and
4 months after subretinal transplantation. Scale bar,
20 mm. Nuclei were stained with TOPRO-3 (blue).
www.moleculartherapy.orggene delivery, the SB100X-mediated gene delivery is relatively safe,
low cost, and provides a long-lasting therapeutic effect. We have pre-
viously shown that cells engineered by the SB100X system secrete
PEDF in culture for at least 1 year.30 Similarly, in vivo studies have
demonstrated that liver cells overexpressed the transgene for 7months
following SB100X-mediated delivery.45,46
In summary, we have shown that SB100X-mediated delivery of the
PEDF gene encoded in pFAR plasmids is efficient in vitro and
in vivo, even when transfecting only 5,000–30,000 pigment epithe-
lial rat cells. The transplanted cells survived for 4 months in rats
and, furthermore, PEDF-expressing cells transplanted to the subre-
tinal space secrete recombinant PEDF. We also observed an inhibi-
tion of the neovascularization in a rat model of CNV. The preclin-
ical experiments presented here aim to bring the TargetAMD
consortium to its goal to conduct a phase 1 clinical trial, in which
IPE cells isolated from AMD patients will be treated ex vivo with
the PEDF gene, followed by immediate autologous subretinal
transplantation.
MATERIALS AND METHODS
Cell Culture
ARPE-19 cells (ATCC, Manassas, VA) were cultured in DMEM
(Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum
(FBS; GIBCO, Paisley, UK) and 1% penicillin/streptomycin/1% am-
photericin B (GIBCO), and maintained in a humidified atmosphereFigure 6. Transfected IPE and RPE Cell Location
(A–W) Fluorescence confocal images of the injected RPE (A–I) and IPE (J–W) cells previously transfected with pFAR
The dissociated RPE and IPE primary cells transfected with Venus (green) (A, C, J, and L) and labeled with CellBrit
space near to the RPE. The areas with primary cells are organized (white squares in A, B, J, and K) (scale bar, 50 mm
Upper panel: RPE-transfected cells are identified in four groups represented in different orthogonal projection con
identified in six groups represented in different orthogonal projection confocal images (N–S). IPE-transfected cells
orthogonal projections (T and V) and at higher magnification by the super-resolution technique (U and W). DAP
INL, inner nuclear layer; ONL, outer nuclear layer.
Molecular Thof 95% air and 5% CO2 at 37C. The medium
was changed three times a week, and cells
were passaged at 70%–80% confluence at a ratio
of 1:3.
Isolation andCulture of Rat Primary IPE and
RPE Cells
The study was performed according to the As-
sociation for Research in Vision and Ophthal-
mology (ARVO) Resolution on the Use of
Animals in Ophthalmic and Vision Researchand approved by the Ethics Committee for Animal Research of the
University of Navarra (protocol approval number 023-13).
Brown Norway rats (8–15 weeks) were used to isolate IPE and RPE
cells. Eyes were cut below the ora serrata, and the anterior segment
and posterior eyecup were separated. In the anterior segment, the
iris was separated from the ciliary body and incubated in trypsin
EDTA (200 mg/L EDTA + 170,000 U Trypsin/L; Lonza, Walkersvile,
MD) at 37C for 10min. IPE cells were isolated by gently brushing the
surface with a fire-polished glass spatula. Cells were centrifuged at
1,200 rpm for 10 min and the pellet was suspended in DMEM:F-12
(ATCC) medium supplemented with 10% FBS and 1% penicillin/
streptomycin/amphotericin B (Lonza; complete medium) and plated
into 24-well tissue culture plates. For RPE isolation, the neural retina
was removed from the posterior eyecup and the RPE/choroid com-
plex was maintained for 3 days in complete DMEM:F-12 medium;
then, RPE cells were gently dislodged by brushing with a fire-polished
glass spatula. The dislodged RPE cells were centrifuged and plated
following the protocol used for IPE cells. IPE and RPE culture me-
dium was changed twice a week.
To confirm the phenotype of primary cells, ARPE-19 and RPE cells
were reacted with antibody to RPE65, CRALBP, and Bestrophin-1,
and IPE cells were reacted with antibody to CK18. Briefly, cells were
fixed in cold methanol overnight at 20C, rinsed, permeabilized
with 0.5%TritonX-100 (Sigma) containing 0.2% sodiumazide (Sigma)4-SB100X-Venus (green) and labeled with CellBrite (red).
e (red) (B, D, K, and M) were transplanted in the subretinal
) and detailed in images (C–E, L, andM) (scale bar, 20 mm).
focal images (F–I). Lower panel: IPE-transfected cells are
numbered 1 and 3 are shown in detail (scale bar, 20 mm) in
I: nuclei in blue. CB, CellBrite; GCL, ganglion cell layer;
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Figure 8. Effect of PEDF-Transfected Rat RPE and IPE Cells on Neovascularization in a Rat Model of Choroidal Neovascularization
Photographs and measurement of CNV area of laser-induced CNV 10 days after treatment with an injection of 5 mL of saline, transplantation with 20,000 PEDF-transfected
RPE cells, and 10,000 PEDF-transfected IPE cells. (A) Photographs of lesions. Each row represents 3 different CNV lesions from 3 different animals. Vessels were stained with
Caveolin-1 (white). (B and C) Measurement of CNV area. The CNV area in rats transplanted with PEDF-transfected cells is approximately 50% less than that of the saline
control (p < 0.05) (B). CNV area of control groups (C). There was no statistical difference among control groups. Area of CNVwas calculated using Fiji software, and data were
presented as a percentage of mean ± SEM (n = 3) versus the saline group. Scale bar, 50 mm. *p < 0.05.
Molecular Therapy: Nucleic Acidsand1%BSA (Sigma) for 30min and incubatedwithprimary antibodies:
RPE65 (mouse monoclonal, ab78036, 1:100, Abcam, Cambridge, UK),
Bestrophin-1 (rabbit polyclonal, orb323221, 1:250, Biorbyt, San Fran-
cisco, CA), CRALBP (rabbit polyclonal, orb182730, 1:250, Biorbyt),
and CK18 (mouse monoclonal, M7010, 1:250, DAKO, Glostrup,
Denmark). After overnight incubation with primary antibodies, cells
were rinsed and incubated with the appropriate secondary antibody:
Alexa Fluor Donkey anti-mouse, A10036, 1:250; (Invitrogen, Paisley,
UK) and Alexa Fluor Donkey anti-rabbit, A21206, 1:250 (Invitrogen).
DAPI (H1200, Vector) was used to label nuclei.
Construction and Production of pFAR4 Derivatives
To construct the pFAR4-ITRs CMV PEDF BGH and pFAR4-ITRs
CMV PEDF-His BGH plasmids, relevant sequences (CMV-PEDF,
CMV-PEDF-His, and BGH) were amplified by PCR using pT2-
CMV-PEDF/EGFP27 as a template. This latter plasmid carries a hu-
man PEDF cDNA that was generated from ARPE-19 cells (ATCC).
The PCR fragments were then inserted stepwise into pFAR4-ITRs,
which is a pFAR4 derivative carrying the ITR sequences amplified
from pT2/BH (a gift from Perry Hackett [Addgene plasmid #
26556, Addgene, Cambridge, MA]). pFAR4 is a miniplasmid vector
that is devoid of antibiotic resistance genes.39 The expression cassette
CMV-SB100x-SV40 was excised from pCMV (CAT)T7-SB100x478 Molecular Therapy: Nucleic Acids Vol. 9 December 2017and introduced into pFAR4, resulting in pFAR4-CMV-SB100X-
SV40. Similarly, the DNA sequence encompassing CAGGS-Venus-
SV40 flanked by both ITRs was excised from pT2-CAGGS-Venus47
and introduced into the pFAR4 vector, resulting in pFAR4-ITRs-
CAGGS Venus.
All pFAR4 constructs were constructed and propagated using a
dedicated bacterial strain (TM # 47-9a) that allows plasmid produc-
tion in the absence of antibiotics.39 Plasmids were purified using
Endofree plasmid preparation kits (Macherey Nagel, Hoerdt,
France). Plasmid integrity and endotoxin levels were assessed using
standard and LAL (Limulus Amoebocyte Lysate, Lonza) procedures,
respectively.
Transfection of ARPE-19 and Primary Cells
All transfections were carried out by electroporation with the Neon
Transfection System using the 10-mL kit (Invitrogen) following the
manufacturer’s protocol. Briefly, 2,000–20,000 cells were suspended
in 11 mL of buffer R and mixed with 2 mL of plasmid mixture (total
DNAconcentrationof 500ng) and electroporated. The ratio of plasmid
to SB100X used was 1:16. Electroporation parameters for ARPE-19
cells were 1350 V, 20 ms, and 2 pulses, and electroporation parameters
for primary RPE and IPE cells were 1,100 V, 20 ms, and 2 pulses.
www.moleculartherapy.orgTransfected cells were plated in 96-well plates. After electroporation,
cells were cultured for 3 days in antibiotic-free DMEM:F-12 medium.
Quantification of PEDF by ELISA
To evaluate PEDF accumulation over 72 hr, 30,000 ARPE-19, pri-
mary rat RPE, and primary rat IPE cells transfected with pFAR4-
CMV-PEDF or pFAR4-Venus were seeded in 96-well plates with a
first change of medium after 3 days; PEDF accumulation was quanti-
fied during the following 3 days in the cell culture medium at 24, 48,
and 72 hr. Phase contrast images were acquired before the cell cul-
tures were terminated.
To determine PEDF secretion, 30,000 PEDF-transfected ARPE-19,
primary rat RPE, and primary rat IPE cells were seeded in 96-well
plates and PEDF secretion during 72 hr was quantified by ELISA at
3, 6, 9, 12, 15, 21, 28, and 56 days after transfection.
PEDF in culture medium was quantified by ELISA (DuoSet Human
SerpinF1/PEDF Kit; R&D Systems, Abingdon, UK) according to
the manufacturer’s protocol. Sample dilution for ARPE-19 cells was
1:5,000 and 1:100 for primary IPE and RPE cells.
PEDF Detection by Western Blot
PEDF protein expression and secretion was analyzed by western blot
as previously reported.48,49 A volume of 7.5 mL was loaded on the gels,
and loadingwas verified by Ponceau S red staining. To visualize PEDF,
blots were reacted with monoclonal anti-PEDF antibody (PEDF
[mouse monoclonal, MAB1059, 1:1,000, Chemicon, Temecula, CA])
followed by horseradish peroxidase-conjugated goat anti-mouse anti-
body (sc2005; 1:10,000, Santa Cruz Biotechnology, Dallas, TX).
Localization of IPE and RPE Cells Transplanted Subretinally
Ten thousand primary IPE, RPE, or ARPE-19 cells were transplanted
to the subretinal space of rats; for localization of the transplanted cells
and evaluation of cell survival, rats were euthanized by cervical dislo-
cation 7 days, 15 days, or 4 months after cell transplantation. Cells
were transfected with pFAR4-Venus when the objective was cell local-
ization and with pFAR4-CMV-PEDF-His to visualize PEDF produc-
tion by immunofluorescence.
Eyes for histological staining or immunological analysis in tissue sec-
tions were fixed in 4% paraformaldehyde (PFA) for 1 hr, transferred
into 30% sucrose for 24 hr prior to embedding in OCT compound
(Tissue TeK, Sakura, Alphen aan den Rijn, Netherlands), and stored
at 20C until use. Samples were sectioned in 12- to 14-mm sections
with a cryostat (HM520 Microm) and collected on “superfrost plus”
glass slices (Thermo, Braunshweig, Germany). Slides were stored at
20C until used. Slides stained with nuclear markers, DAPI (Vector)
or TOPRO-3 (T3605, Life Technologies, Carlsbad, CA), were observed
andphotographedwith afluorescence (Axio ImagerM1,Zeiss,Oberko-
chen, Germany) or confocal (LSM510 and LSM800; Zeiss) microscope.
Eyes to be analyzed in a flat mount were enucleated, and the choroid-
RPE complexwas fixed in 4%PFA for 1 hr at 4C, rinsedwith PBS, andflat mounted in a cross. Samples were then stained with TOPRO-3 or
DAPI and visualized by confocal microscope. For immunostaining,
flat mounts were permeabilized with 0.25% Triton X-100 and 1%
BSA for 30 min. Anti-PEDF (mouse monoclonal, MAB1059,
1:1,000, Chemicon), anti-Histidine (6-His, goat polyclonal, NBP1-
25939, 1:400, Novus, Cambridge, UK), and zonula occludens with
Alexa 594 (ZO-1, mouse monoclonal, 1364021A, 1:100, Invitrogen)
antibodies were used for immuno-localization. After rinsing in PBS,
flat mounts were incubated with the appropriate secondary antibodies
(Alexa Fluor Donkey anti-mouse 488, A21202, 1:250 for PEDF and
Alexa Fluor Donkey anti-Goat 594, A11058, 1:250 for 6-His) and
counterstained with a nuclear marker (DAPI or TOPRO-3). A
confocal microscope (LSM510 and LSM800 with Airyscan; confocal
super-resolution imaging, Zeiss) was used to acquire immunofluores-
cence images and orthogonal projections over the z plane.
In order to be sure the injected and observed RPE and IPE cells were
the transfected cells, we stained the primary cells in culture with an
infrared (647 nm) CellBrite dye (Cytoplasmic Membrane Labeling
Kit, 1:200; Biotium, Hayward, CA), which labels cell cytoplasmic
membranes and organelles. For the CellBrite staining, 1 mL was
mixed in 106 RPE and IPE cells in DMEM-F12 supplemented with
10% FBS. The medium was removed, and the cells were rinsed with
PBS and incubated for 40 min under cell culture conditions in the
staining solution. Then, the cells were centrifuged three times at
1,200 rpm during 10 min and rinsed with PBS three times, and fresh
medium was added before the injection procedure.
Laser-Induced CNV Model and Subretinal Cell Transplantation
Brown Norway male rats (8–10 weeks) were anesthetized, and eyes
were dilated with a mixture of phenylephrine (7.8 mg/mL) and tropi-
camide (3 mg/mL) eye drops. Four laser photocoagulation spots
(250-mW intensity, 0.05 s, and 75-mm spot size) were made concen-
trically around the optic nerve using a coverslip as a contact lens.
Rupture of Bruch’s membrane was confirmed by bubble formation.
Laser rupture sites with hemorrhage or subretinal bleeding at the
time of laser application were excluded from analysis.50
To evaluate the efficacy of the treatment, 2 days after inducing CNV,
10,000 IPE or 20,000 RPE cells transfected with pFAR4-CMV-PEDF-
His were transplanted subretinally. For subretinal transplantation,
rats were anesthetized by intraperitoneal administration of a mixture
of ketamine (Imalgene 1000, Merial laboratories, Barcelona, Spain;
75 mg/kg) and xylazine (Xilagesic 2%, Calier laboratories, Barcelona,
Spain; 10 mg/kg). For transplantation, pupils were dilated, eyes were
anesthetized with a double anesthetic (Tetracaine chlorohydrate
1 mg/10 mL and oxibuprocaine chlorohydrate 4 mg/10 mL; Alcon
cusí, Barcelona, Spain) and stabilized using a suture, and the superior
conjunctiva and subconjunctival tissue was cut to expose the sclera. A
hole was made into the subretinal space using a 27G needle, and
the appropriate number of cells suspended in 5 mL of PBS was infused
using a 25G de Juan cannula (Synergetics, O’Fallon, MO) attached
to a 25-mL Hamilton syringe (Hamilton Messtchnik, Höchst, Ger-
many). The scleral wound was not sutured; oxytetracycline ointmentMolecular Therapy: Nucleic Acids Vol. 9 December 2017 9
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to the wound. In this experiment, six groups of 3 rats each were
treated as follows: 3 rats were transplanted with 10,000 IPE cells trans-
fected with the Venus gene, 3 rats were transplanted with 10,000 IPE
cell transfected with the PEDF-His gene, 3 rats were transplanted with
20,000 RPE cells transfected with the Venus gene, 3 rats were trans-
planted with 20,000 RPE cells transfected with the PEDF-His gene,
3 rats were transplanted with saline, and 3 rats served as non-trans-
planted controls.
Ten days after cell transplantation, rats were euthanized and the RPE/
choroid complex was processed for analysis in flat mount following
the protocol described above for caveolin-1 immunostaining. The
CNV area in retinal flat mounts was identified with caveolin-1
staining (Rabbit polyclonal, #3238, 1:400, Cell Signaling, Leiden,
Netherlands), followed by reaction with secondary antibody Alexa
Fluor Goat anti-Rabbit 488 (A11008, 1:250; Invitrogen). Flat mounts
were photographed using a confocal microscope to obtain a single im-
age. The CNV areas were quantified with Fiji software (a distribution
of ImageJ) V1.48q by 2 investigators who were blinded to the study
groups.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analysis was performed
using the SPSS 20 program (SPSS, Chicago, IL). In vitro studies were
analyzed by using an ANOVA for repeated measurements; a one-way
ANOVAwith Bonferroni andDunnett’s post hoc tests was performed
for the CNV area results after confirming the normal distribution of
the data.
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